Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: Phase i study of the Shiga Breast Cancer Study Group

Breast Cancer

Volumn 16, Issue 1, 2009, Pages 37-41

  Abe, Hajime ^a,b   Ogawa, Hiroki ^b   Okino, Takashi ^b   Kato, Makoto ^b   Sako, Hirotaka ^b   Sano, Haruo ^b   Shimomatsuya, Takumi ^b   Suwa, Hirofumi ^b   Higashide, Shunichi ^b  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Shiga Breast Cancer Study Group   (Japan)

Author keywords

Adjuvant therapy; Bi weekly schedule; Breast cancer; Docetaxel

Indexed keywords

CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RISK; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INCIDENCE; LACRIMATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; ADJUVANT CHEMOTHERAPY; BREAST TUMOR; DRUG ADMINISTRATION; JAPAN; LYMPH NODE METASTASIS; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAPAN; LYMPHATIC METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; TAXOIDS;

EID: 59649085574     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-008-0054-z     Document Type: Article

References (17)

1. I Adachi T Watanabe S Takashima M Narabayashi N Horikoshi H Aoyama 1996 A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancer Br J Cancer 73 210 6 (Pubitemid 26028336)
2. M Martin T Pienkowski J Mackey M Pawlicki JP Guastalla C Weaver 2005 Adjuvant docetaxel for node-positive breast cancer N Engl J Med 352 2302 13 (Pubitemid 40740554)
3. IC Smith SD Heys AW Hutcheon ID Miller S Payne FJ Gilbert 2002 Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel J Clin Oncol 20 1456 66 (Pubitemid 34260523)
4. Early Breast Cancer Trialists' Collaborative Group 2005 Effects of chemotherapy and hormonal therapy for breast cancer on recurrence and 15-year survival: an overview of the randomized trials Lancet 365 1687 717
5. N Wolmark J Wang E Mamounas J Bryant B Fisher 2001 Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical adjuvant Breast and Bowel Project B-18 J Natl Cancer Inst Monogr 30 96 102 (Pubitemid 32319246)
6. A Goldhirsch JH Glick RD Gelber HJ Senn 1998 Meeting highlights: international consensus panel on the treatment of primary breast cancer J Natl Cancer Inst 90 1601 8 (Pubitemid 28523434)
7. Early Breast Cancer Trialists' Collaborative Group 1988 Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomized trials among 28,896 women N Engl J Med 319 1681 2
8. Early Breast Cancer Trialists' Collaborative Group 1998 Polychemotherapy for early breast cancer: an overview of the randomized trials Lancet 352 930 42
9. IC Henderson DA Berry GD Demetri CT Cirrincione LJ Goldstein S Martino 2003 Improved outocomes from adding sequential paclitaxel but not from escalating of doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer J Clin Oncol 21 976 83 (Pubitemid 46594124)
10. H Roche P Fumoleau M Spielmann JL Canon T Delozier D Serin 2006 Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients; the FNCLCC PACS 01 trial J Clin Oncol 24 5664 71 (Pubitemid 46631307)
11. J Baselga JM Tabernero 2001 Weekly docetaxel in breast cancer: applying clinical data to patient therapy Oncologist 6 Suppl 3 26 9 (Pubitemid 32423183)
12. Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschenes L, Douma J, et al. 304 Study Group. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol. 1999;17:1413-24.
13. Chan S, Friedrichs K, Noel D, Pinter T, Van Belle S, Vorobiof D, et al. 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999;17:2341-54.
14. J Tabernero MA Climent A Lluch J Albanell JB Vermorken A Barnadas 2004 A multicentre, randomized phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann Oncol 15 1358 65 (Pubitemid 39295024)
15. E Shin M Ishitobi M Hiraoia K Fujitani H Mishima I Nishisho 2000 Phase I study of docetaxel administered by bi-weekly infusion to patients with metastatic breast cancer Anticancer Res 20 4721 6 (Pubitemid 32127717)
16. JA Sparano M Wang S Martino V Jones E Perez T Saphner 2007 Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in operable breast cancer: results of intergroup trial E1199 Proc Am Soc Clin Oncol part I 25 6s abstr 516
17. HD Bear S Anderson RE Smith CE Geyer Jr EP Mamounas B Fisher 2006 Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: national surgical adjuvant breast and bowel project protocol B-27 J Clin Oncol 24 2019 27 (Pubitemid 46622110)